Meridian Bioscience Inc.

Formerly NASDAQ: VIVO
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 17 pages Director Indemnification Agreement
12/34/56
EX-10.1
from 8-K 2 pages February 8, 2022 Andrew S. Kitzmiller 9287 Steeplechase Drive Cincinnati, Oh 45242 Dear Andrew, This Letter Serves to Confirm Our Offer, of the Chief Financial Officer Position With Meridian Bioscience, Reporting Directly to the Jack Kenny, CEO. Your Work Location Will Be 3471 River Hills Dr, Cincinnati, Oh 45244. Your Tentative Start Date Is February 21, 2022. This Offer Is as Follows: Compensation · Salary: Your Base Salary Will Be $380,000 Annually. You Will Be Paid Bi-Weekly Every Other Friday
12/34/56
EX-10.3
from 10-Q 8 pages Meridian Bioscience, Inc. 2021 Omnibus Award Plan Fiscal Year 2022 Performance Share Unit Award Agreement Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***]
12/34/56
EX-10.2
from 10-Q 5 pages Cash-Based Incentive Compensation Plan Fiscal Year 2022 Officers Level 8 Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***]
12/34/56
EX-10.1
from 10-Q 5 pages Cash-Based Incentive Compensation Plan Fiscal Year 2022 Chief Executive Officer Level 9 Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***]
12/34/56
EX-10.8
from 10-K 8 pages Meridian Bioscience, Inc. 2021 Omnibus Award Plan Nonqualified Stock Option Agreement
12/34/56
EX-10.7
from 10-K 8 pages Meridian Bioscience, Inc. 2021 Omnibus Award Plan Restricted Share Unit Award Agreement Time-Based
12/34/56
EX-10.4
from 10-Q 8 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Amendment No. 3 to Share Purchase Agreement
12/34/56
EX-10.3
from 10-Q 9 pages Amendment to Share Purchase Agreement
12/34/56
EX-10.2
from 10-Q 5 pages Cash-Based Incentive Compensation Plan Fiscal Year 2021 Officers Level 8 Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***]
12/34/56
EX-10.1
from 10-Q 5 pages Cash-Based Incentive Compensation Plan Fiscal Year 2021 Chief Executive Officer Level 9 Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***]
12/34/56
EX-10
from S-8 25 pages Meridian Bioscience, Inc. 2021 Omnibus Award Plan
12/34/56
EX-10.16
from 10-K 13 pages Amendment No. 2 to Share Purchase Agreement
12/34/56
EX-10.8
from 10-K 4 pages Meridian Bioscience, Inc. 2012 Stock Incentive Plan Nonqualified Stock Option Agreement
12/34/56
EX-10.7
from 10-K 5 pages Meridian Bioscience, Inc. 2012 Stock Incentive Plan Restricted Share Unit Award Agreement Time-Based
12/34/56
EX-10.6
from 10-K 7 pages Meridian Bioscience, Inc. Israeli Appendix to the Meridian Bioscience, Inc. 2012 Stock Incentive Plan
12/34/56
EX-10.2
from 8-K 9 pages First Amendment and Consent
12/34/56
EX-10.1
from 8-K 10 pages Voting Agreement
12/34/56
EX-10.1
from 10-Q 3 pages Cash-Based Incentive Compensation Plan Fiscal Year 2020 Officers Level 8
12/34/56
EX-10.1
from 8-K 23 pages Amended and Restated Employment Agreement
12/34/56